RenovoRx Net Worth
RenovoRx Net Worth Breakdown | RNXT |
RenovoRx Net Worth Analysis
RenovoRx's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including RenovoRx's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of RenovoRx's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform RenovoRx's net worth analysis. One common approach is to calculate RenovoRx's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares RenovoRx's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing RenovoRx's net worth. This approach calculates the present value of RenovoRx's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of RenovoRx's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate RenovoRx's net worth. This involves comparing RenovoRx's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into RenovoRx's net worth relative to its peers.
Enterprise Value |
|
To determine if RenovoRx is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding RenovoRx's net worth research are outlined below:
| RenovoRx may become a speculative penny stock | |
| RenovoRx appears to be risky and price may revert if volatility continues | |
| RenovoRx has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (10.23 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| RenovoRx currently holds about 10.77 M in cash with (10.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.19. | |
| Latest headline from news.google.com: Analysts Expect Breakeven For RenovoRx, Inc. Before Long - Yahoo Finance |
RenovoRx uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in RenovoRx. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to RenovoRx's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know RenovoRx's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as RenovoRx is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading RenovoRx backward and forwards among themselves. RenovoRx's institutional investor refers to the entity that pools money to purchase RenovoRx's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tower Research Capital Llc | 2024-09-30 | 4.1 K | Ubs Group Ag | 2024-09-30 | 2.2 K | Royal Bank Of Canada | 2024-06-30 | 203 | Bank Of America Corp | 2024-09-30 | 196 | Family Firm Inc | 2024-09-30 | 0.0 | Blackrock Inc | 2024-09-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Renaissance Technologies Corp | 2024-09-30 | 0.0 | Bank Of Montreal | 2024-09-30 | 975 K | Bmo Capital Markets Corp. | 2024-09-30 | 975 K |
Follow RenovoRx's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 32.38 M.Market Cap |
|
Project RenovoRx's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (8.03) | (7.63) | |
| Return On Capital Employed | (45.04) | (42.78) | |
| Return On Assets | (8.03) | (7.63) | |
| Return On Equity | 3.07 | 3.22 |
When accessing RenovoRx's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures RenovoRx's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of RenovoRx's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in RenovoRx's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of RenovoRx. Check RenovoRx's Beneish M Score to see the likelihood of RenovoRx's management manipulating its earnings.
Evaluate RenovoRx's management efficiency
RenovoRx has return on total asset (ROA) of (0.7008) % which means that it has lost $0.7008 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5512) %, meaning that it created substantial loss on money invested by shareholders. RenovoRx's management efficiency ratios could be used to measure how well RenovoRx manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 3.22 in 2025, despite the fact that Return On Tangible Assets are likely to grow to (7.63). At this time, RenovoRx's Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 4.7 M in 2025, whereas Liabilities And Stockholders Equity is likely to drop slightly above 1.6 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.26) | (0.28) | |
| Tangible Book Value Per Share | (0.26) | (0.28) | |
| Enterprise Value Over EBITDA | (1.77) | (1.86) | |
| Price Book Value Ratio | (7.07) | (6.72) | |
| Enterprise Value Multiple | (1.77) | (1.86) | |
| Price Fair Value | (7.07) | (6.72) | |
| Enterprise Value | 25.8 M | 44.5 M |
The management strategies employed by RenovoRx's are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific RenovoRx insiders, such as employees or executives, is commonly permitted as long as it does not rely on RenovoRx's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases RenovoRx insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
RenovoRx time-series forecasting models is one of many RenovoRx's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary RenovoRx's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
RenovoRx Earnings per Share Projection vs Actual
RenovoRx Corporate Management
| CGMA CPA | Controller VP | Profile | |
| Ronald CPA | VP Controller | Profile | |
| James Ahlers | Chief Officer | Profile | |
| Leesa Gentry | Senior Operations | Profile | |
| Angela Nelms | Chief Officer | Profile | |
| Ryan Witt | Senior Partnerships | Profile | |
| Ramtin MD | Chairman Founder | Profile |
Additional Tools for RenovoRx Stock Analysis
When running RenovoRx's price analysis, check to measure RenovoRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RenovoRx is operating at the current time. Most of RenovoRx's value examination focuses on studying past and present price action to predict the probability of RenovoRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RenovoRx's price. Additionally, you may evaluate how the addition of RenovoRx to your portfolios can decrease your overall portfolio volatility.